Law360, New York (February 25, 2009, 12:00 AM ET) -- The U.S. Food and Drug Administration has accused a Ranbaxy Laboratories Ltd. facility in India of submitting false information and test results for certain approved drugs and pending drug applications.
The agency said Wednesday it has halted its review of any new or pending drug approval applications with data generated from the Ranbaxy plant in Paonto Sahib and asked the facility to submit a correction action plan to address concerns with integrity of its data.
The action relates only to the Paonto Sahib facility. It applies...
FDA Says Ranbaxy Falsified Data From India Plant
To view the full article, take a free trial now.
